← Eichor
Condition: Relapse Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Relapse

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma
Phase 1 · 1 location(s) · Emory University · NCT06492954
tDCS to Decrease Opioid Relapse (UH3)
NA · 1 location(s) · Butler Hospital · NCT06432465
Tracking Mutations in Cell Free Tumour DNA to Predict Relapse in Early Colorectal Cancer
Phase N/A · 71 location(s) · Royal Marsden NHS Foundation Trust · NCT04050345
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
Phase 1/Phase 2 · 128 location(s) · University of Birmingham · NCT04625907
Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
Phase 2 · 1 location(s) · New York Medical College · NCT07013565
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
EARLY_Phase 1 · 1 location(s) · Shanghai Cell Therapy Group Co.,Ltd · NCT06732232
Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymph
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT04484012
Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis
Phase 1/Phase 2 · 1 location(s) · Peking University People's Hospital · NCT06873100
A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases
EARLY_Phase 1 · 5 location(s) · Nanjing Legend Biotech Co. · NCT07095075
Renal Adjuvant MultiPle Arm Randomised Trial
Phase 3 · 35 location(s) · University College, London · NCT03288532
A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or R
Phase 3 · 1 location(s) · Genrix (Shanghai) Biopharmaceutical Co., Ltd. · NCT07452198
Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone
Phase 3 · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06561854
Maintenance Zanzalintinib With Etoposide After HDCT in GCT
Phase 1/Phase 2 · 1 location(s) · Indiana University · NCT06937866
MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia
NA · 1 location(s) · King Hussein Cancer Center · NCT07371403
Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma
Phase 2 · 1 location(s) · Evopoint Biosciences Inc. · NCT07545603
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Phase 2 · 13 location(s) · New Approaches to Neuroblastoma Therapy Consortium · NCT06450041
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880
High Dose Rate (HDR) Brachytherapy Salvage After Prostatectomy
Phase N/A · 1 location(s) · Clinica Universidad de Navarra, Universidad de Navarra · NCT06982469
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
Phase 2 · 24 location(s) · Giselle Sholler · NCT04696029
Combined Relapse Prediction Model for Resectable Non-Small Cell Patients - a Prospective Clinical Feasibility Trial
NA · 1 location(s) · Chang Gung Memorial Hospital · NCT06262386
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
NA · 1 location(s) · Cionic, Inc. · NCT05964829
An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treatin
EARLY_Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07101705
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcuta
Phase 1 · 12 location(s) · Hoffmann-La Roche · NCT07667322
Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual/Recurrent Disease - the TiMBER Trial
Phase N/A · 1 location(s) · OHSU Knight Cancer Institute · NCT07726602
Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell L
Phase 2 · 23 location(s) · Xynomic Pharmaceuticals, Inc. · NCT03936153
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
Phase 1 · 4 location(s) · Catapult Therapeutics · NCT04704323
Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia
Phase 2 · 1 location(s) · Daihong Liu · NCT07321301
All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06158412
REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)
Phase 2 · 18 location(s) · Stichting Hemato-Oncologie voor Volwassenen Nederland · NCT04523428
Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced
NA · 1 location(s) · Wuxi People's Hospital · NCT06430502
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.